Genomics Research

 
Stock Quotes for Genomics Research top ^
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for ghdx investment picks
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for ghdx investment picks
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for rosg investment picks

 
ETF Quotes for Genomics Research top ^
  • Holdings: Pharmacyclics Inc , Amgen Inc , Regeneron Pharmaceuticals Inc , Sigma-Aldrich Corp , Gilead Sciences Inc ,
  • Morningstar Rating: 3 Stars
Sign-up for pbe investment picks

 
News Articles for Genomics Research top ^
Laboratory Corporation of America ® Holdings (LabCorp ® ; NYSE: LH) announced today the launch of Enlighten Health Genomics, a new business that builds on the diagnostic potential of Next-Generation Sequencing (NGS) technology.
Sign-up for LabCorp’s Enlighten Health Launches Innovative Genomics Initiative investment picks
Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study Data Submitted for Presentation at Medical Meeting Later this Year REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints investment picks
Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress investment picks
REDWOOD CITY, Calif.
Sign-up for Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference investment picks
Results Suggest that Oncotype DX® Colon Cancer Test May Reduce Medical Costs Associated with Stage II Disease While Increasing Patient Well-being REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics investment picks
http://media.marketwire.com/attachments/201310/67979_randcapital.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1128175&ProfileId=051205&sourceType=1 BUFFALO, NY --
Sign-up for Rand Partners With Innovate NY Fund to Invest in Personalized Cancer Medicine Business, Empire Genomics, LLC investment picks
17% Increase in Test Volume, 11% Increase in Total Revenue and 29% Increase in International Product Revenue Compared to Prior Year Positive Topline Results from Additional, Large Clinical Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints Positive Results from Second, Large Ductal Carcinoma In Situ (DCIS) Clinical Validation Study Submitted for Presentation at the San Antonio Breast Cancer Symposium in December Conference Call Today at 4:30 p.m. ET REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Second Quarter 2014 Financial Results and Business Progress investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G018691-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/7/22/11G018691/Rosetta_logo-324671456267.jpg PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - July 22, 2014) - Rosetta Genomics Ltd.
Sign-up for Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1127086&ProfileId=051205&sourceType=1 PRINCETON, NJ and REHOVOT, ISRAEL --
Sign-up for Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Prognosis and Treatment of Prostate Cancer investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1130246&ProfileId=051205&sourceType=1 PRINCETON, NJ and REHOVOT, ISRAEL --
Sign-up for Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer investment picks
Initial Target of the Parabase Sequencing Service is the Neonatal Intensive Care Unit of U.S. Hospitals with the Goal of Improving Early Diagnosis of Genetic Diseases SOUTH EASTON, Mass.
Sign-up for Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform investment picks
CGI's proprietary genomic test has been CLIA and NYS licensed to stratify CLL and SLL patient into three distinct outcome groups: favorable, intermediate, and unfavorable It is the only comprehensive test to report on 20 clinically-validated and disease-relevant genomic regions focused on CLL and SLL The proprietary genomic test addresses a growing market of over 120,000 patients for the most common form of leukemia (CLL/SLL) RUTHERFORD, N.J., Aug.
Sign-up for Cancer Genetics, Inc. Releases the Only Comprehensive Genomic Test to Diagnose & Stratify the Most Common Form of Leukemia (CLL) investment picks
World-renowned cancer centers and Illumina, Inc. (NASDAQ:ILMN) today announced the formation of the Actionable Genome Consortium (AGC), an effort to recommend openly published standards for the widespread use of next-generation sequencing to guide decision-making in clinical oncology.
Sign-up for Actionable Genome Consortium Forms with Cross Disciplinary Leaders from World-Renowned Cancer Institutions investment picks
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the acquisition of Precision Genome Engineering, Inc., or Pregenen, a privately held biotechnology company headquartered in Seattle, Washington.
Sign-up for bluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Genomics Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Genetic Research  |  Next: Gentiva Health Services